GlassScriptPhysician profile
Katherine Visman
NPI 1508518457
$2,632.49
in general payments reported to CMS, 2019-2025
20 companies · $668 in 2025
The $668 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $332 · 2023: $686 · 2024: $947 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.73 | 2022-2024 | Wegovy |
| Lilly USA, LLC | $258.96 | 2022-2025 | Zepbound |
| Neurocrine Biosciences, INC. | $246.59 | 2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $228.33 | 2023-2024 | Fasenra |
| Teva Pharmaceuticals USA, INC. | $137.76 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Spravato |
| Amgen INC. | $121.82 | 2024 | Tepezza |
| Biogen, INC. | $115.43 | 2025 | Tysabri |
| Horizon Therapeutics Plc | $114.41 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.32 | 2025 | Jardiance |
| Corcept Therapeutics | $109.42 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $102.91 | 2023 | Rexulti |
| Intuitive Surgical, INC. | $96.73 | 2022 | |
| Acadia Pharmaceuticals INC | $88.80 | 2024 | Nuplazid |
| Exact Sciences Corporation | $86.31 | 2025 | The Cologuard Plus Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $85.66 | 2023 | |
| Tactile Systems Technology INC | $82.95 | 2025 | Flexitouch Plus, Nimbl |
| Vertex Pharmaceuticals Incorporated | $76.96 | 2025 | |
| Cvrx, INC. | $68.43 | 2025 | Barostim Neo System |
| Rhythm Pharmaceuticals, INC. | $22.97 | 2024 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Visman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.